SCHEMBL6444458

SCHEMBL6444458

N#Cc1c(OCc2ccccn2)nc(N)nc1C1=CCCO1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGMT P16455 1/20 0.42
TLR7 Q9NYK1 4/20 0.37
TLR8 Q9NR97 1/20 0.35
ADORA1 P30542 10/20 0.34
ADORA2A P29274 9/20 0.34
ADORA2B P29275 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
HRH4 Q9H3N8 1/20 0.33
TUBB4A P04350 1/20 0.33
TUBB P07437 1/20 0.33
TUBA3C P0DPH7 1/20 0.33
TUBA1B P68363 1/20 0.33
TUBA4A P68366 1/20 0.33
TUBB4B P68371 1/20 0.33
TUBB3 Q13509 1/20 0.33
TUBB2A Q13885 1/20 0.33
TUBB8 Q3ZCM7 1/20 0.33
TUBA3E Q6PEY2 1/20 0.33
TUBA1A Q71U36 1/20 0.33
TUBA1C Q9BQE3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6441734 0.81 ADORA1 (0.41) ADORA1ADORA2AADORA2BADORA3ALDH1A1
SCHEMBL6441414 0.81 MGMT (0.55) MGMTTLR7TLR8ADORA1ADORA2A
SCHEMBL5041645 0.80 ADORA1 (0.57) MGMTADORA1ADORA2AADORA2B
SCHEMBL6443675 0.80 MGMT (0.48) MGMTTLR7TLR8ADORA1ADORA2A
SCHEMBL5041663 0.78 ADORA2A (0.56) MGMTADORA1ADORA2AADORA2BADORA3
SCHEMBL5039926 0.76 ADORA2A (0.52) MGMTTLR7TLR8ADORA1ADORA2A
SCHEMBL5044782 0.76 ADORA2A (0.56) MGMTADORA1ADORA2AADORA2BADORA3
SCHEMBL6443053 0.76 ADORA2A (0.60) MGMTADORA1ADORA2ASYKALDH1A1
SCHEMBL6443183 0.76 MGMT (0.42) MGMTTLR7TLR8ADORA1ADORA2A
SCHEMBL6443037 0.76 SQOR (0.51) MGMTTLR7TLR8ADORA1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 MGMT 3075/4885TLR7 1772/4885TLR8 2074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.